The estimated Net Worth of Daniel P Witt is at least 12.7 百万$ dollars as of 20 June 2014. Daniel Witt owns over 87,500 units of Repligen stock worth over 11,591,452$ and over the last 21 years Daniel sold RGEN stock worth over 1,110,775$.
Sign up
Daniel Witt RGEN stock SEC Form 4 insiders trading
Daniel has made over 11 trades of the Repligen stock since 2006, according to the Form 4 filled with the SEC. Most recently Daniel exercised 87,500 units of RGEN stock worth 428,750$ on 20 June 2014.
The largest trade Daniel's ever made was exercising 87,500 units of Repligen stock on 20 June 2014 worth over 428,750$. On average, Daniel trades about 15,691 units every 179 days since 2004. As of 20 June 2014 Daniel still owns at least 80,833 units of Repligen stock.
You can see the complete history of Daniel Witt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Daniel Witt's mailing address?
Daniel's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453.
Insiders trading at Repligen
Over the last 22 years, insiders at Repligen have traded over 118,224,292$ worth of Repligen stock and bought 160,440 units worth 1,459,521$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Glenn P Muir、Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of 3,015,702$. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth 1,139,034$.
What does Repligen do?
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
What does Repligen's logo look like?
Complete history of Daniel Witt stock trades at Repligen
Repligen executives and stock owners
Repligen executives and other stock owners filed with the SEC include:
-
Anthony Hunt,
President, Chief Executive Officer, Director -
Jon Snodgres,
Chief Financial Officer -
Ralf Kuriyel,
Senior Vice President - Research and Development -
Anthony J. Hunt,
CEO, Pres & Director -
Jon K. Snodgres,
Chief Financial Officer -
Ralf Kuriyel,
Sr. VP of R&D -
Karen Dawes,
Independent Chairperson of the Board -
Glenn Muir,
Independent Director -
Thomas Ryan,
Independent Director -
Nicolas Barthelemy,
Independent Director -
Rohin Mhatre,
Independent Director -
Carrie Eglinton,
Director -
James Slaughter,
Chief HR Officer -
James R. Bylund,
Chief Operating Officer -
Christine Gebski,
Sr. VP of Filtration & Chromatography -
Ken Elmer,
Global Head of HR -
Rachel Goodrich,
VP of Marketing -
Stephen Tingley,
VP of Global Sales -
Squire Servance,
Sr. VP, Gen. Counsel & Corp. Sec. -
Sondra S. Newman,
Global Head of Investor Relations -
Jim Bylund,
Sr. VP of Operations & Information Technology -
Jason K Garland,
CFO -
Glenn L Md Cooper,
Director -
James R Rusche,
Senior Vice President -
John Cox,
Director -
Howard Benjamin,
-
Roy T Eddleman,
10% owner -
Christine Gebski,
See Remarks -
G William Miller,
Director -
Timothy Scott Harris,
-
Barbara Burnim Day,
Vice President -
Daniel W Muehl,
CFO -
Partners L P/Ilbiotechnolog...,
-
Alfred Lewis Goldberg,
Director -
Walter C Herlihy,
PRESIDENT, CEO -
Michael A Griffith,
Director -
Daniel P Witt,
Vice President -
Jonathan I Lieber,
CFO -
Earl Webb Henry,
Director -
William J Kelly,
Vice President -
Alexander Rich,
Director -
Partners L P/Ilbiotechnolog...,
-
Hal Landy,
Vice President -
Paul Schimmel,
Director -
Laura Whitehouse,
Vice President -
Robert J Hennessey,
Director -
Margaret Pax,
-
Konstantin Konstantinov,
-
Martin D Madaus,
-
James Bylund,
Chief Operating Officer -
Olivier Loeillot,
Chief Executive Officer